Matthew L. Rizk

2.3k total citations
55 papers, 1.5k citations indexed

About

Matthew L. Rizk is a scholar working on Pharmacology, Epidemiology and Molecular Medicine. According to data from OpenAlex, Matthew L. Rizk has authored 55 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pharmacology, 22 papers in Epidemiology and 20 papers in Molecular Medicine. Recurrent topics in Matthew L. Rizk's work include Antibiotics Pharmacokinetics and Efficacy (25 papers), Antibiotic Resistance in Bacteria (20 papers) and Pneumonia and Respiratory Infections (15 papers). Matthew L. Rizk is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (25 papers), Antibiotic Resistance in Bacteria (20 papers) and Pneumonia and Respiratory Infections (15 papers). Matthew L. Rizk collaborates with scholars based in United States, Netherlands and France. Matthew L. Rizk's co-authors include James C. Liao, Linh M. Tran, Elizabeth G. Rhee, Katherine Young, Mallika Lala, Ling Zou, Amanda Paschke, Maria C Losada, Joan R. Butterton and Nicholas A. Kartsonis and has published in prestigious journals such as PLoS ONE, Analytical Chemistry and Clinical Infectious Diseases.

In The Last Decade

Matthew L. Rizk

52 papers receiving 1.5k citations

Peers

Countries citing papers authored by Matthew L. Rizk

Since Specialization

Citations

This map shows the geographic impact of Matthew L. Rizk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew L. Rizk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew L. Rizk more than expected).

Fields of papers citing papers by Matthew L. Rizk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew L. Rizk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew L. Rizk. The network helps show where Matthew L. Rizk may publish in the future.

Co-authorship network of co-authors of Matthew L. Rizk

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew L. Rizk. A scholar is included among the top collaborators of Matthew L. Rizk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew L. Rizk. Matthew L. Rizk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparison of Molnupiravir Exposure‐Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID‐19 2025 ·Clinical and Translational Science ·Akshita Chawla, Ruthie Birger, Brian M. Maas, Youfang Cao, Hong Wan, Julie Strizki, Arthur Fridman, Amanda Paschke, Carisa De Anda, Wei Gao, Matthew L. Rizk, Wendy Painter, Wayne Holman, (unknown), George R. Painter, Julie A. Stone	0
2	Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK‐3655 in Individuals With Pre‐Cirrhotic MASH 2025 ·Alimentary Pharmacology & Therapeutics ·Annaswamy Raji, Ira Gantz, Michael F. Crutchlow, Heather A. Flynn, (unknown), Anthony Rodgers, (unknown), Matthew L. Rizk, (unknown), Keith D. Kaufman, Samuel S. Engel, (unknown)	4
3	Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance 2023 ·JAC-Antimicrobial Resistance ·Jason A. Roberts, David P. Nicolau, Ignacio Martín‐Loeches, C Andrew DeRyke, Maria C Losada, Jiejun Du, Munjal Patel, Matthew L. Rizk, Amanda Paschke, Luke F. Chen	10
4	Factors Influencing COVID‐19 Risk: Insights From Molnupiravir Exposure‐Response Modeling of Clinical Outcomes 2023 ·Clinical Pharmacology & Therapeutics ·Akshita Chawla, Ruthie Birger, Hong Wan, Youfang Cao, Brian M. Maas, Amanda Paschke, Carisa De Anda, Matthew L. Rizk, Julie A. Stone	6
5	Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance 2021 ·International Journal of Antimicrobial Agents ·David P. Nicolau, Jan J. De Waele, Joseph L. Kuti, Luzelena Caro, Kajal Larson, Brian Yu, (unknown), Zhen Zeng, Elizabeth G. Rhee, Matthew L. Rizk	27
6	Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population 2020 ·American Journal of Perinatology ·Jocelyn Y. Ang, Antonio Arrieta, John S. Bradley, Zufei Zhang, Brian Yu, Matthew L. Rizk, Matthew G. Johnson, Elizabeth G. Rhee	13
7	Thorough QTc Study of a Single Supratherapeutic Dose of Relebactam in Healthy Participants 2020 ·Clinical Pharmacology in Drug Development ·(unknown), Yang Liu, (unknown), Terry O’Reilly, Francheska Colón‐González, Evan Friedman, Mallika Lala, Elizabeth G. Rhee, Matthew L. Rizk	3
8	A Systematic Review of Renal Function Estimation Equations 2019 ·Current Pharmacology Reports ·(unknown), Wei Gao, Matthew L. Rizk	2
9	A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam 2019 ·International Journal of Infectious Diseases ·(unknown), Zufei Zhang, Fred Racine, Donna Carr, Jin Wu, Katherine Young, Matthew L. Rizk	35
10	Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection 2018 ·Journal of Infection and Chemotherapy ·(unknown), Kajal Larson, Hwa-ping Feng, (unknown), (unknown), Matthew L. Rizk	11
11	Novel Gastroretentive Controlled Release Formulations for Once-Daily Administration: Assessment of Clinical Feasibility and Formulation Concept for Raltegravir 2016 ·Therapeutic Innovation & Regulatory Science ·Rajesh Krishna, Matthew L. Rizk, Patrick Larson, Valerie Schulz, Evan Friedman, Pranav Gupta, (unknown), Alyson Connor, John McDermott, Ronald L. Smith, Philip Evans	2
12	A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir 2016 ·Clinical Pharmacokinetics ·Matt S. Anderson, Sauzanne Khalilieh, Ka Lai Yee, Rachael Liu, Fan Li, Matthew L. Rizk, (unknown), Azra Hussaini, Ivy Song, Lisa Ross, Joan R. Butterton	25
13	Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV‐infected children 4 weeks to 18 years of age 2015 ·The Journal of Clinical Pharmacology ·Matthew L. Rizk, Lihong Du, (unknown), Larissa Wenning, Hedy Teppler, (unknown), Bobbie Graham, (unknown), Sharon Nachman, Andrew Wiznia, Carol Worrell, Betsy Smith, Edward P. Acosta	13
14	Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age 2015 ·Journal of the Pediatric Infectious Diseases Society ·Sharon Nachman, (unknown), Edward P. Acosta, Hedy Teppler, (unknown), Bobbie Graham, T. Fenton, Xia Xu, Matthew L. Rizk, Stephen A. Spector, Lisa M. Frenkel, (unknown), Edward Handelsman, Andrew Wiznia	24
15	Structure-Based Prediction of Anti-infective Drug Concentrations in the Human Lung Epithelial Lining Fluid 2015 ·Pharmaceutical Research ·Pyry A. J. Välitalo, (unknown), Matthew L. Rizk, Sandra A. G. Visser, Meindert Danhof, (unknown), Piet H. van der Graaf, J. G. Coen van Hasselt	12
16	Raltegravir Pharmacokinetics in Neonates Following Maternal Dosing 2014 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Diana F. Clarke, Edward P. Acosta, Matthew L. Rizk, Yvonne J. Bryson, Stephen A. Spector, Lynne Mofenson, Edward Handelsman, Hedy Teppler, (unknown), Deborah Persaud, (unknown), (unknown), Mark Mirochnick	35
17	Redox homeostasis phenotypes in RubisCO‐deficient Rhodobacter sphaeroides via ensemble modeling 2010 ·Biotechnology Progress ·Matthew L. Rizk, (unknown), Kevin M. Smith, F. Robert Tabita, James C. Liao	11
18	Ensemble modeling for strain development of l-lysine-producing Escherichia coli 2009 ·Metabolic Engineering ·Carolina A. Contador, Matthew L. Rizk, Juan A. Asenjo, James C. Liao	57
19	Ensemble Modeling for Aromatic Production in Escherichia coli 2009 ·PLoS ONE ·Matthew L. Rizk, James C. Liao	46
20	Ensemble Modeling of Metabolic Networks 2008 ·Biophysical Journal ·Linh M. Tran, Matthew L. Rizk, James C. Liao	191

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact